Labiotech.eu

Allecra Therapeutics Urinary Tract Infections

News and Trends 26 Mar 2018

New Antibiotic for Urinary Tract Infections Gets Positive Phase II Results

Allecra Therapeutics has obtained positive Phase II study results for its new urinary tract infection antibiotic, supporting the launch of a Phase III trial. Allecra Therapeutics, a French-German biotech, has obtained positive Phase II trial results for its lead antibiotic candidate for treating urinary tract infections. The drug, AAU101, was given to patients intravenously with cefepemine, another antibiotic […]

March 26, 2018 - 1 minutemin - By Alexander Burik

Best in Biotech 26 Mar 2018

The 10 Biotech Venture Capital Firms in Europe to Watch in 2018

Who’s funding the biotech industry in Europe? I’ve gathered a list of some of the most active European biotech venture capital firms that will be setting the pace of the industry this year. Biotech can do great things, from curing deadly diseases to helping make the plastics industry more sustainable. But there is a common […]

March 26, 2018 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Mar 2018

Biotech VC Goes After Disrupting Animal Health and Nutrition

The French biotech VC Seventure, known for its investments in microbiome health, has launched a €24M fund focused on companies developing animal health and nutrition applications. A new venture capital fund called AVF has been launched today to support animal health and nutrition companies. With €24M at its first closing, the fund created by Seventure Partners in partnership […]

March 23, 2018 - 2 minutesmins - By Alexander Burik

imgonline com ua CompressToSize C9Ojq1qDlJ8Cl

News and Trends 23 Mar 2018

Researchers Give Sight to the Blind With Stem Cell Patch

UK researchers have successfully restored vision in two blind patients by transplanting a stem cell patch into their eyes. Scientists at University College London and Moorfields Eye Hospital, London, have used a stem cell patch to successfully restore vision in two patients with age-related macular degeneration (AMD) in a Phase I trial. Following the stem […]

March 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 22 Mar 2018

French Biotech Signs a Deal to Fight Antibiotic Resistance

Deinove is licensing a portfolio of antibiotics for multi-drug resistant bacteria from Redx Pharma. Deinove, based in Montpellier, France, has signed an agreement to use synthetic molecules developed by UK biotech Redx to treat lethal anitbiotic-resistant infections. Redx’s molecules are a new class of antibiotics targeting an enzyme involved in bacterial DNA replication in Gram-negative bacteria. Deinove plans to […]

March 22, 2018 - 1 minutemin - By Alexander Burik

News and Trends 21 Mar 2018

A Personalized Genetic Test for Breast Cancer Arrives in Europe

Agendia will launch a next-generation sequencing test in the EU to determine the chances of metastasis in breast cancer patients. Agendia, a US-Dutch biotech specializing in personalized medicine and molecular diagnostics, has obtained CE marking for the MammaPrint BluePrint Kit, a diagnostic device for breast cancer that uses next-generation sequencing technology. The kit can help clinicians identify […]

March 21, 2018 - 2 minutesmins - By Alexander Burik

Interview 21 Mar 2018

Do Phages Hold the Key to Modulating the Microbiome?

The human microbiome is emerging as a target for treating a wide range of diseases, but it’s still a young field and there are lots of unknowns. Philip discussed with the CEO of BiomX whether phages may be the key to targeting specific bacterial strains in the microbiome. In the last decade, scientists have found […]

March 21, 2018 - 3 minutesmins - By Alexander Burik

Oxford Nanopore Technologies Fundraising

News and Trends 20 Mar 2018

DNA Sequencing Unicorn Oxford Nanopore Raises £100M Round at £1.5Bn Valuation

Undeterred by competitors, Oxford Nanopore, one of the few unicorns in the biotech space, has secured £100M (€113M) to continue growing its unique next-generation sequencing platform. Oxford Nanopore is one of the best-funded biotechs in Europe, having raised £507.3M (€578M) in total, and famous for its “DNA-reading gadget the size of a Mars bar that sells for $1,000.” The company plans to […]

March 20, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 20 Mar 2018

Oxford Firm Develops Better Test for ALS Diagnosis

Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […]

March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 20 Mar 2018

Why It’s the Best Time to Be in Cell and Gene Therapy

Cell and gene therapies are here, and they’re here to stay. We stopped to chat about the future of the field with Alexander Vos last week at Bio Europe Spring. The cell and gene therapy space has been given a big boost in the last couple of years. Since 2016, GSK’s gene therapy Strimvelis is available […]

March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Spanish Research Stem Cell ALS Treatment

News and Trends 19 Mar 2018

Early Research in Bone Marrow Transplants Could Treat ALS

Early stage research from Spain could lead to a treatment for amyotrophic lateral sclerosis (ALS) using adult stem cells from bone marrow to stop progressive muscle paralysis. Researchers from the Neuroscience Institute at the Universidad Miguel Hernández (UMH) in Elche, Alicante, and the Spanish National Research Council (CSIC) aim to test a stem cell treatment for […]

March 19, 2018 - 3 minutesmins - By Alexander Burik

More News! 19 Mar 2018

Could the Microbiome Treat Side Effects of Stem Cell Transplants?

MaaT Pharma, based in Lyon, has received authorization to launch a Phase II trial for its therapy, which targets the gut microbiota to treat complications from stem cell transplants. MaaT Pharma will launch a Phase II trial for MaaT013, a therapy for treating acute graft-versus-host disease — a major complication of hematopoietic stem cell transplantation […]

March 19, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New Antibiotic for Urinary Tract Infections Gets Positive Phase II Results

The 10 Biotech Venture Capital Firms in Europe to Watch in 2018

Biotech VC Goes After Disrupting Animal Health and Nutrition

Researchers Give Sight to the Blind With Stem Cell Patch

French Biotech Signs a Deal to Fight Antibiotic Resistance

A Personalized Genetic Test for Breast Cancer Arrives in Europe

Do Phages Hold the Key to Modulating the Microbiome?

DNA Sequencing Unicorn Oxford Nanopore Raises £100M Round at £1.5Bn Valuation

Oxford Firm Develops Better Test for ALS Diagnosis

Why It’s the Best Time to Be in Cell and Gene Therapy

Early Research in Bone Marrow Transplants Could Treat ALS

Could the Microbiome Treat Side Effects of Stem Cell Transplants?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!